Pharmaceutical Kickbacks: Paying for Prescriptions Through Doctors and Intermediaries

Pharmaceutical kickbacks buy prescriptions and drug business with improper payments or benefits. The payment may reach a doctor as a speaking fee, a pharmacy as a rebate or a patient through a manufacturer-funded foundation. Taxpayers fund the resulting Medicare and Medicaid bills, while patients depend on advice that the manufacturer has paid to influence. If you see who is selected, what is paid and which prescriptions follow, you may know more about the deal than the invoice says.

What Is a Pharmaceutical Kickback?

A pharmaceutical kickback is something of value offered, paid, requested or received to improperly influence prescribing, purchasing or referrals. The federal Anti-Kickback Statute reaches knowing and willful arrangements involving drugs or services that federal health care programs, including Medicare, Medicaid and TRICARE, may pay for. It covers the party buying the business and the party accepting the benefit, including payments routed through someone else.

Cash is only one form. Meals, travel, consulting fees, free products and services can all supply the benefit. A manufacturer can also reward a specialty pharmacy with more patients. The commercial question is what the recipient is expected to do in return: write a prescription, recommend a switch, keep a patient refilling or give a drug preferred access.

A paid service can also be a way to reward prescribing. We examine who needed the work, who chose the recipient and what determined the payment.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks work by putting a benefit at a decision that can generate paid drug business. A manufacturer may pay a doctor who prescribes, a pharmacy that recommends or dispenses, or a pharmacy benefit manager that influences which drugs a plan covers. A foundation can pay the patient’s share while Medicare pays the rest.

A pharmacy benefit manager works between the drug plan and the pharmacy, handling coverage and reimbursement arrangements. A patient-support hub can investigate benefits and coordinate assistance applications.

A sales team sees speaker spending, a pharmacy sees referrals and a plan sees prescriptions. Connecting them explains how a manufacturer can buy business without submitting the government’s bill itself.

Do Doctors Still Get Kickbacks From Pharmaceutical Companies?

Recent civil settlements continue to address pharmaceutical kickbacks to doctors. In May 2026, Takeda reached a civil settlement to resolve allegations involving Trintellix speaker payments and high-end restaurant meals. The government alleged that speakers were selected to induce prescribing and that repeated programs provided no additional educational benefit.

The practical detail is how a doctor gets onto the paid list, stays there and gets invited back. A selection spreadsheet tied to prescribing tells a different story from a contract describing education.

Speaker Programs Where the Talk Was Optional

Novartis admitted in its 2020 civil settlement that some sales representatives intended honoraria to induce doctors to prescribe more of its drugs. Groups of doctors repeatedly dined together and sometimes rotated who received the speaking payment. Novartis also paid honoraria for events that never happened.

One representative arranged fake restaurant receipts and used the dinner budget to buy gift cards for high-prescribing doctors. The doctors received speaking fees too. The educational program survived on paper after the dinner itself had disappeared.

Salix’s civil admissions show another way to defeat an expense control. Representatives reported doctors as attending when they had not, making the meal cost per person appear lower. At some prerecorded programs, the presentation went unplayed or was placed where it could not readily be seen or heard.

Consulting and Research Payments Tied to Prescribing

Consulting fees and research payments can buy prescribing when the paid work becomes a pretext for rewarding the drug choice. The government’s Amgen data-purchase case shows how the design can change inside the business.

The original Deep Dive program would have paid doctors to report how they treated bone-cancer patients, whether or not they prescribed Xgeva. The government alleged that Amgen increased the payments and restricted them to doctors who prescribed Xgeva. Its marketing team also gained access to the identities of participating doctors.

The original proposal, revised contract and recipient list explain the alleged change more clearly than the invoice’s description of data services. For advisory boards, the question also reaches what the company expected from attendance: advice from the physician, or an audience for its own sales message.

Free Samples and Reimbursement Assurances

Free samples and reimbursement assurances can make using a manufacturer’s product financially attractive to the practice or facility. In its 2026 EyePoint settlement announcement, the Justice Department alleged that excessive free DEXYCU samples and an Assurance Program induced surgery facilities to purchase and dispense the drug.

Under the alleged arrangement, EyePoint compensated facilities if insurers denied a DEXYCU claim or paid less than the facility’s purchase cost. The product treated inflammation after cataract surgery. The benefit included taking the facility’s reimbursement risk off its hands.

Free Diagnostic Tests Feeding Sales Calls

Free diagnostic testing can supply both a benefit to a practice and leads for the manufacturer’s sales force. QOL Medical admitted facts about that loop in its 2024 Sucraid resolution.

QOL distributed free breath-test kits and paid a laboratory to analyze them. The laboratory sent results to providers and to QOL. The company passed information about positive results to its sales force and tracked whether representatives converted those results into Sucraid prescriptions.

Specialty Pharmacies Paid to Keep Patients Refilling

Specialty-pharmacy kickbacks can take the form of patient referrals tied to refill performance. Novartis’s Exjade network made that incentive explicit: the pharmacy with the highest adherence score would receive 60% of patient referrals that had not been assigned to a particular pharmacy. Accredo admitted agreeing to that allocation plan.

The score measured how long patients continued ordering refills. Accredo also admitted knowing that the calculation included patients who stopped because of side effects or a physician’s instruction. A medically directed stop could therefore count against a pharmacy competing for the next patient.

The government’s amended complaint described the pressure on another pharmacy in the network:

The nursing calls were part of that commercial arrangement. Accredo admitted that its call protocols emphasized common side effects while omitting less common, more severe risks. When Novartis ended the extra-referral incentive, Accredo stopped assigning nurses to make the calls the following month.

The scorecard, referral allocation and call instructions show what the manufacturer was rewarding. The patient heard a healthcare professional. The pharmacy also had a sales target to meet.

Prior Authorization and Preferred Pharmacies

Prior-authorization work connects the prescription to the insurer’s decision to pay. In the 2021 Kaléo civil settlement, the government alleged that the manufacturer directed Evzio prescriptions to preferred pharmacies submitting false claims and providing prescriber kickbacks.

That arrangement puts pharmacy routing beside the coverage submission. We examine who directed the prescription to the pharmacy, what benefits accompanied that routing and what the pharmacy represented to obtain payment.

Copay Foundations and the Patient’s Share

Manufacturer-funded copay foundations can carry an indirect kickback by paying the patient’s share of a particular drug while generating a Medicare claim for the balance. The commercial attraction appears plainly in the government’s Sensipar allegations against Amgen: funding copays allegedly cost Amgen more than supplying free medicine would have, but it generated Medicare claims and revenue.

The fund’s design determines whose prescriptions benefit. A disease category can be narrowed around a donor’s product. Eligibility rules can favor its patients. Information about which applications were approved can travel back to the company funding the assistance.

Advanced Care Scripts acknowledged relaying foundation data to Teva so Teva could connect its donations with spending on Copaxone patients. When funds were closed, the pharmacy supplied updates on patients waiting for assistance. After learning that a fund had reopened, it promptly submitted a batch of applications consisting almost entirely of Copaxone patients.

The timing mattered alongside the donation. The manufacturer knew the waiting demand, and the pharmacy was ready when assistance became available. Donation records, fund-opening notices and application timestamps can reveal coordination that disappears when each organization is viewed separately.

Patient assistance is also a competitive issue. The government alleged that Astellas promoted the availability of funds limited to its drug’s class as an advantage for Xtandi over competing drugs. The charitable benefit had allegedly become part of the sales pitch.

PBM Kickbacks Can Hide in Another Drug’s Discount

Pharmacy benefit manager kickbacks can involve payment for formulary access, the placement that affects a drug’s availability under a plan. The payment may appear in concessions on entirely different products.

AstraZeneca settled allegations about Nexium’s exclusive status on certain Medco formularies. The government alleged that AstraZeneca supplied the benefit through price concessions on Prilosec, Toprol XL and Plendil. Looking only at the Nexium account would miss where the alleged payment was recorded.

A 2020 USC Schaeffer Center study, The Association Between Drug Rebates and List Prices, examined branded-drug price estimates from 2015 through 2018. It found that increases in estimated rebates were associated with increases in list prices. The paper explains the incentive:

That distinction gives an insider a more useful question than the size of the rebate alone: what decision earns the next payment? We examine what the pharmacy benefit manager earns and what the plan pays alongside the decision about which drug gets access.

The plan’s payment to the pharmacy benefit manager, the manager’s payment to the pharmacy and the manufacturer’s rebate are separate flows. The difference between the first two is the spread. The formulary agreement, concessions across products and service-fee terms show where the incentives sit. We connect those terms to the decision the manufacturer was paying to influence.

Institutional Pharmacies and Drug Switching

Institutional-pharmacy kickbacks can pay for recommendations that reach many patients through the same pharmacy. Omnicare settled allegations that it accepted Amgen payments for programs designed to switch Medicaid patients from a competing drug to Aranesp.

The government alleged performance rebates tied to market-share or volume thresholds, alongside grants, speaker fees, consulting services, data fees, dinners and travel. The pharmacy was the recipient, and the alleged aim was a change in treatment. A switching protocol and a rebate schedule can describe the same incentive in different departments.

What Evidence Is Needed to Prove Fraud?

We work with you to connect the payment, the decision it bought and the government claims that followed. Contracts describe what the company said it was buying. Internal instructions, actual work and payment records show how the arrangement operated.

A record can also explain a change. Why did eligibility for a survey begin requiring a prescription? Why did nurse calls stop when the referral incentive ended? Why was a batch of patients ready at the moment a foundation reopened? These are concrete connections between a commercial decision and what happened afterward.

You may work in sales operations, pharmacy services, patient access, finance or compliance and see only part of that chain. We work with you to connect your knowledge to the payments, prescriptions and claims that give it meaning.

From a Kickback to a False Claims Act Case

A claim for drugs or services resulting from an Anti-Kickback Statute violation can be a false claim under the False Claims Act. A manufacturer can be responsible for a false bill it knowingly causes a pharmacy or provider to submit.

The connection to those claims is part of the case we build with you. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Open Payments Shows Only Part of the Transaction

Open Payments identifies reported industry transfers to health professionals and teaching hospitals. Its payment entries sit separately from prescription claims. Connecting a reported fee to speaker selection, actual work and prescribing requires the other records.

Samples, discounts, rebates and donations to copay foundations fall outside the payment file. Those omissions include several of the routes through which manufacturers allegedly bought business. An insider’s knowledge of the arrangement can connect the visible payment to the decisions behind it, or explain a payment channel that the public database never shows.

When You Know What the Payment Bought

If you know why a doctor, pharmacy or patient fund received the money, speak with our whistleblower experts about the business it bought. We build your strongest pharmaceutical kickback whistleblower case with you, connecting the payment to the decisions and government claims it produced. We bring in pharmaceutical kickback whistleblower lawyers who understand these arrangements and stay beside you through the case.